SK1202003A3 - Combinations of dalfopristine/quinupristine with cefpirome - Google Patents

Combinations of dalfopristine/quinupristine with cefpirome Download PDF

Info

Publication number: SK1202003A3
Authority: SK; Slovakia
Prior art keywords: cefpirome; dalfopristin; quinupristin; quinupristine; dalfopristine
Prior art date: 2000-08-03

Application number

SK120-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Celine Feger

Philippe Moreillon

Jacques Vouillamoz

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-03

Filing date

2001-08-02

Publication date

2003-07-01

2001-08-02 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2003-07-01 Publication of SK1202003A3 publication Critical patent/SK1202003A3/sk

Links

DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 title claims abstract description 26
229960000466 cefpirome Drugs 0.000 title claims abstract description 25
SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 title claims abstract description 20
WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 title claims abstract description 17
PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 claims description 16
239000004480 active ingredient Substances 0.000 claims description 14
238000001802 infusion Methods 0.000 claims description 12
229940052337 quinupristin/dalfopristin Drugs 0.000 claims description 11
PPKJUHVNTMYXOD-CEHYXHNTSA-N quinupristin-dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C/C(=O)NC\C=C/C(/C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)CC2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-CEHYXHNTSA-N 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 5
239000003708 ampul Substances 0.000 claims description 4
230000002195 synergetic effect Effects 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
239000000126 substance Substances 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 6
239000000243 solution Substances 0.000 description 14
238000011282 treatment Methods 0.000 description 14
229960002615 dalfopristin Drugs 0.000 description 9
108700028430 dalfopristin Proteins 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 8
206010014665 endocarditis Diseases 0.000 description 7
108010071077 quinupristin-dalfopristin Proteins 0.000 description 7
238000000034 method Methods 0.000 description 6
230000000844 anti-bacterial effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229940020707 synercid Drugs 0.000 description 5
208000035143 Bacterial infection Diseases 0.000 description 4
241000191967 Staphylococcus aureus Species 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical class C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
108010063483 Streptogramin Group A Proteins 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
229960003085 meticillin Drugs 0.000 description 3
229960005442 quinupristin Drugs 0.000 description 3
108700028429 quinupristin Proteins 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000295644 Staphylococcaceae Species 0.000 description 2
108010063479 Streptogramin Group B Proteins 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
238000007689 inspection Methods 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000011294 monotherapeutic Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
238000005303 weighing Methods 0.000 description 2
-1 2-aminothiazol-4-yl Chemical group 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000191938 Micrococcus luteus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000006481 glucose medium Substances 0.000 description 1
244000000059 gram-positive pathogen Species 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Thyristors (AREA)
Peptides Or Proteins (AREA)

SK120-2003A 2000-08-03 2001-08-02 Combinations of dalfopristine/quinupristine with cefpirome SK1202003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0010245A FR2812549B1 (fr)	2000-08-03	2000-08-03	Associations dalfopristine/quinupristine avec le cefpirome
PCT/FR2001/002520 WO2002011751A2 (fr)	2000-08-03	2001-08-02	Associations dalfopristine/quinupristine avec le cefpirome

Publications (1)

Publication Number	Publication Date
SK1202003A3 true SK1202003A3 (en)	2003-07-01

Family

ID=8853264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK120-2003A SK1202003A3 (en)	2000-08-03	2001-08-02	Combinations of dalfopristine/quinupristine with cefpirome

Country Status (28)

Country	Link
US (2)	US7005416B2 (pl)
EP (1)	EP1313500B1 (pl)
JP (1)	JP2004505926A (pl)
KR (1)	KR100808715B1 (pl)
CN (1)	CN1256982C (pl)
AR (1)	AR033992A1 (pl)
AT (1)	ATE279204T1 (pl)
AU (2)	AU2001284095B2 (pl)
BR (1)	BR0112897A (pl)
CA (1)	CA2418023A1 (pl)
CZ (1)	CZ2003290A3 (pl)
DE (1)	DE60106463T2 (pl)
DK (1)	DK1313500T3 (pl)
EA (1)	EA007713B1 (pl)
ES (1)	ES2230358T3 (pl)
FR (1)	FR2812549B1 (pl)
HU (1)	HU227455B1 (pl)
IL (1)	IL154237A0 (pl)
MX (1)	MXPA03000959A (pl)
NO (1)	NO20030483L (pl)
NZ (1)	NZ523982A (pl)
PE (1)	PE20020264A1 (pl)
PL (1)	PL204278B1 (pl)
PT (1)	PT1313500E (pl)
SK (1)	SK1202003A3 (pl)
TN (1)	TNSN01116A1 (pl)
WO (1)	WO2002011751A2 (pl)
ZA (1)	ZA200300903B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107420042B (zh) *	2017-09-25	2023-03-31	中国地质大学（武汉）	一种基于六自由度并联机构的海底钻机自动调平系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0867676A (ja) *	1994-03-30	1996-03-12	Eisai Kagaku Kk	保護アミノチアゾリル酢酸誘導体
US5464616A (en) *	1994-08-04	1995-11-07	Synphar Laboratories, Ind.	6β-substituted penicillanic acids as beta-lactamase inhibitors
US5686441A (en) *	1995-08-04	1997-11-11	Syphar Laboratories, Inc.	Penam sulfones as β-lactamase inhibitors
FR2755857B1 (fr) *	1996-11-19	1998-12-24	Rhone Poulenc Rorer Sa	Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
US6187746B1 (en) *	1997-12-16	2001-02-13	Rhone-Poulenc Rorer S.A.	Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
US6465428B1 (en) *	1999-08-27	2002-10-15	Aventis Pharma S.A.	Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime

2000
- 2000-08-03 FR FR0010245A patent/FR2812549B1/fr not_active Expired - Fee Related
2001
- 2001-07-26 PE PE2001000759A patent/PE20020264A1/es not_active Application Discontinuation
- 2001-08-01 TN TNTNSN01116A patent/TNSN01116A1/fr unknown
- 2001-08-01 AR ARP010103684A patent/AR033992A1/es unknown
- 2001-08-02 PL PL365075A patent/PL204278B1/pl not_active IP Right Cessation
- 2001-08-02 AU AU2001284095A patent/AU2001284095B2/en not_active Ceased
- 2001-08-02 AU AU8409501A patent/AU8409501A/xx active Pending
- 2001-08-02 AT AT01963045T patent/ATE279204T1/de not_active IP Right Cessation
- 2001-08-02 CA CA002418023A patent/CA2418023A1/fr not_active Abandoned
- 2001-08-02 NZ NZ523982A patent/NZ523982A/en not_active IP Right Cessation
- 2001-08-02 EA EA200300214A patent/EA007713B1/ru unknown
- 2001-08-02 CZ CZ2003290A patent/CZ2003290A3/cs unknown
- 2001-08-02 JP JP2002517086A patent/JP2004505926A/ja active Pending
- 2001-08-02 HU HU0300682A patent/HU227455B1/hu not_active IP Right Cessation
- 2001-08-02 SK SK120-2003A patent/SK1202003A3/sk unknown
- 2001-08-02 EP EP01963045A patent/EP1313500B1/fr not_active Expired - Lifetime
- 2001-08-02 CN CNB018148573A patent/CN1256982C/zh not_active Expired - Fee Related
- 2001-08-02 DK DK01963045T patent/DK1313500T3/da active
- 2001-08-02 IL IL15423701A patent/IL154237A0/xx unknown
- 2001-08-02 WO PCT/FR2001/002520 patent/WO2002011751A2/fr not_active Ceased
- 2001-08-02 ES ES01963045T patent/ES2230358T3/es not_active Expired - Lifetime
- 2001-08-02 BR BR0112897-3A patent/BR0112897A/pt not_active IP Right Cessation
- 2001-08-02 PT PT01963045T patent/PT1313500E/pt unknown
- 2001-08-02 KR KR1020037001575A patent/KR100808715B1/ko not_active Expired - Lifetime
- 2001-08-02 DE DE60106463T patent/DE60106463T2/de not_active Expired - Lifetime
- 2001-08-02 MX MXPA03000959A patent/MXPA03000959A/es unknown
- 2001-08-03 US US09/920,810 patent/US7005416B2/en not_active Expired - Lifetime
2003
- 2003-01-30 NO NO20030483A patent/NO20030483L/no not_active Application Discontinuation
- 2003-01-31 ZA ZA200300903A patent/ZA200300903B/en unknown
2006
- 2006-01-04 US US11/325,919 patent/US20060122103A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR033992A1 (es)	2004-01-21
TNSN01116A1 (fr)	2005-11-10
WO2002011751A2 (fr)	2002-02-14
DK1313500T3 (da)	2005-02-14
DE60106463T2 (de)	2005-10-13
WO2002011751A3 (fr)	2002-06-13
KR100808715B1 (ko)	2008-02-29
HUP0300682A3 (en)	2004-09-28
US7005416B2 (en)	2006-02-28
KR20030022351A (ko)	2003-03-15
CZ2003290A3 (cs)	2003-05-14
ZA200300903B (en)	2003-11-10
FR2812549B1 (fr)	2003-03-21
EA007713B1 (ru)	2006-12-29
HUP0300682A2 (hu)	2003-08-28
EA200300214A1 (ru)	2003-06-26
ATE279204T1 (de)	2004-10-15
NO20030483D0 (no)	2003-01-30
PE20020264A1 (es)	2002-05-20
BR0112897A (pt)	2003-06-10
AU8409501A (en)	2002-02-18
FR2812549A1 (fr)	2002-02-08
CA2418023A1 (fr)	2002-02-14
CN1256982C (zh)	2006-05-24
NO20030483L (no)	2003-01-30
AU2001284095B2 (en)	2007-04-05
ES2230358T3 (es)	2005-05-01
EP1313500A2 (fr)	2003-05-28
JP2004505926A (ja)	2004-02-26
PL365075A1 (pl)	2004-12-27
US20020037890A1 (en)	2002-03-28
DE60106463D1 (de)	2004-11-18
NZ523982A (en)	2004-10-29
PL204278B1 (pl)	2009-12-31
HU227455B1 (en)	2011-06-28
EP1313500B1 (fr)	2004-10-13
MXPA03000959A (es)	2003-06-09
CN1449290A (zh)	2003-10-15
IL154237A0 (en)	2003-07-31
PT1313500E (pt)	2005-02-28
HK1058305A1 (en)	2004-05-14
US20060122103A1 (en)	2006-06-08

Publication	Publication Date	Title
Norden	1975	Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin
Landman et al.	1997	Management of infections due to resistant enterococci: a review of therapeutic options.
Norden	1983	Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents
HUP0002662A2 (hu)	2000-12-28	Lizosztafint magában vagy antibiotikus kombinációban tartalmazó gyógyászati készítmény, amely stafilokokkusz fertőzések kezelésére alkalmazható
Archer et al.	1983	Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies
O'Reilly et al.	1992	Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin
US20200171121A1 (en)	2020-06-04	Cationic antimicrobial peptides
JP2012501349A (ja)	2012-01-19	オリタバンシンの単回用量を用いる治療の方法
Petitclerc et al.	2007	Efficacy of a lactoferrin-penicillin combination to treat β-lactam-resistant Staphylococcus aureus mastitis
US20230364065A1 (en)	2023-11-16	Antibiotic combination therapies
Wright et al.	1982	Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis
Johnson et al.	1987	Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis
US6465428B1 (en)	2002-10-15	Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
US5658887A (en)	1997-08-19	Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivatite
Henry et al.	1986	Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low-or high-dose streptomycin
Berry et al.	1986	Imipenem therapy of experimental Staphylococcus epidermidis endocarditis
KR100808715B1 (ko)	2008-02-29	달포프리스틴/퀴누프리스틴과 세프피롬의 배합물
Smith	2017	Isoxazolyl penicillins: oxacillin, cloxacillin, dicloxacillin, and flucloxacillin
Prins et al.	1998	Once-daily aminoglycosides: practical guidelines
HK1058305B (en)	2006-12-29	Combinations of dalfopristine/quinupristine with cefpirome
Zar et al.	1985	In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis
Pawar et al.	2011	Newer antibiotics for musculoskeletal infections
KR20190134456A (ko)	2019-12-04	항균 조성물